Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
26.4 EUR | 0.00% | -1.49% | +70.32% |
Apr. 29 | Donaldson Agrees to Acquire 49% Stake in Medica | MT |
Apr. 26 | Response Plus Unit Closes Prometheus Medical Acquisition | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+70.32% | 121M | - | ||
+33.63% | 50.93B | B- | ||
-0.09% | 42.12B | B | ||
+49.62% | 42.05B | A | ||
-4.96% | 29.18B | C | ||
+11.18% | 26.02B | B- | ||
-21.95% | 18.9B | B | ||
+8.61% | 13.21B | B+ | ||
+24.73% | 12.17B | B+ | ||
+28.31% | 12.16B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MDC Stock
- Ratings Medica S.p.A.